Dianthus reports FY2024 net loss $85M; Phase 2 gMG top-line on track for 2H'25

Dianthus Therapeutics, Inc. /DE/

Net loss of $85.0M ($2.55 per share) in FY2024, vs $43.6M ($8.45 per share) in FY2023.
Cash, cash equivalents and investments of $357.0M as of Dec 31, 2024, providing runway into 2H'27.
R&D expenses rose to $83.1M from $32.8M, driven by clinical and CMC costs for DNTH103.
Phase 2 MaGic gMG trial on track for top-line results in 2H'25; Phase 3 CIDP interim analysis in 2H'26.
Appointed John C. King as CCO and Sujay Kango to Board on March 5, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.